Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Medical Countermeasures

    Sirnaomics Advances RNAi-Based Prophylactics and Therapeutics to Battle SARI Caused by 2019-nCoV

    By Global Biodefense StaffJanuary 24, 2020
    Share
    Facebook LinkedIn Reddit Email

    Sirnaomics Inc., a leading biopharmaceutical company in discovery and development of novel RNAi therapeutics, announced today that it has mobilized its research teams both in USA and China to develop novel RNAi-based prophylactics and therapeutics for treatment of patients suffering from Severe Acute Respiratory Infection (SARI) caused by the 2019 novel Coronavirus (2019-nCoV).

    Based on U.S. Centers for Disease Control (CDC), the outbreak of respiratory illness that is caused by a novel coronavirus (termed “2019-nCov”) and was first detected in Wuhan City, Hubei Province, China, continues to spread. In addition to confirmed cases in multiple provinces in China (as of January 24, 2020), human-to-human infections with the virus have been confirmed in Thailand, Japan, Taiwan, South Korea, Singapore, Vietnam and USA. The total confirmed number of patients infected by 2019-nCoV is 929, with 26 deaths in Hubei Province, China.

    The Sirnaomics R&D team has an established track record of using siRNA prophylactics and therapeutics to treat SARS coronavirus, H5N1 influenza and other respiratory viral infections, with multiple animal models including non-human primate.  The team’s expertise covers siRNA drug design (silencing the most critical viral genes), respiratory tract siRNA delivery formulation, large scale GMP drug production and clinical investigations.  To fight against SARI caused by the 2019-nCoV infection, Sirnaomics team has already identified potentially potent siRNAs, specifically targeting the viral genes critical for the viral infection and replication.  Collaborating with laboratories having cell culture models of 2019-nCoV infection, Sirnaomics expects to develop multiple siRNA drug candidates.

    Patrick Lu, PhD, President and Chief Executive Officer of Sirnaomics, stated, “This is a critical time for treating SARI caused by the 2019-nCoV to mitigate further spreading of the deadly disease. RNAi as a naturally evolved antiviral mechanism has been demonstrated in various in vitro and in vivo models.  Our team’s in-depth knowledge and experience using RNAi technology to fight respiratory viral infection in the previous SARS outbreak will add on to our antiviral weaponry to fight SARI. The unique siRNA drug design and chemical modification, respiratory specific siRNA delivery formulation, and the handheld nebulizer device are providing a clear pathway for developing novel siRNA therapeutics and prophylactics against 2019-nCoV infection.”

    David Evans, Ph.D. Chief Scientific Officer of Sirnaomics, stated, “Sirnaomics recognizes the need for rapid identification of a safe and effective way to treat this devasting disease.  The process of developing siRNA therapeutics offers the advantage of rapid identification of druggable targets that could potentially impact the 2019-nCoV virus. Our R&D team is well positioned to contribute to developing a solution and potentially bring valuable treatment options to patients with this high unmet medical need.”

    About Sirnaomics , Inc.

    Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The company’s mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a great deal of combined experience in the biopharmaceutical industry, financial, clinical and business management in both the USA and China. The Company is supported by funding from institutional investors and corporate partnerships. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology and anti-fibrotic therapeutics.

    COVID-19 Magazine Edition 28 Jan 2020
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleCEPI to Fund Development of Multiple Candidate Vaccines Against the Novel Coronavirus
    Next Article Bill & Melinda Gates Foundation Commits $10 Million to Global Response to 2019-nCoV

    Related Stories

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    COVID Moonshot Consortium Announces Crowd-Sourced Small Molecule Discovery

    November 11, 2023

    WHO Updates Guidance on Treatments for COVID-19

    November 11, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.